Get started
Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

TEVJF chart


Full chart

TEVJF upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪21.48 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.17 USD
Net income (FY)
‪−1.67 B‬ USD
Revenue (FY)
‪16.77 B‬ USD
Shares float
‪1.13 B‬
Beta (1Y)
−0.23

Employees


Employees (FY)
‪36.17 K‬
Change (1Y)
‪−1.06 K‬ −2.84%
Revenue / Employee (1Y)
‪463.76 K‬ USD
Net income / Employee (1Y)
‪−46.04 K‬ USD

About Teva Pharmaceutical Industries Limited


Sector
Health Technology
Industry
Pharmaceuticals: Generic
CEO
Richard Francis
Website
tevapharm.com
Headquarters
Tel Aviv
Founded
1901
ISIN
IL0006290147
FIGI
BBG000HD4X32
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Check out other big names from the same industry as TEVJF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TEVJF news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

TEVJF highest yielding bonds


TEVA5295244
Teva Pharmaceutical Finance Netherlands III BV 4.75% 09-MAY-2027
Yield to maturity
—
Maturity date
May 9, 2027
TEVA4608603
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028
Yield to maturity
—
Maturity date
Mar 1, 2028
TEVA6082388
Teva Pharmaceutical Finance Netherlands III BV 6.0% 01-DEC-2032
Yield to maturity
—
Maturity date
Dec 1, 2032
TEVA6082389
Teva Pharmaceutical Finance Netherlands IV BV 5.75% 01-DEC-2030
Yield to maturity
—
Maturity date
Dec 1, 2030
TEVA5549923
Teva Pharmaceutical Finance Netherlands III BV 7.875% 15-SEP-2029
Yield to maturity
—
Maturity date
Sep 15, 2029
TEVA5549924
Teva Pharmaceutical Finance Netherlands III BV 8.125% 15-SEP-2031
Yield to maturity
—
Maturity date
Sep 15, 2031
TEVA5295245
Teva Pharmaceutical Finance Netherlands III BV 5.125% 09-MAY-2029
Yield to maturity
—
Maturity date
May 9, 2029
TEVA4608604
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028
Yield to maturity
—
Maturity date
Mar 1, 2028
TEVA.GJ
Teva Pharmaceutical Finance Co. LLC 0.25% 01-FEB-2026
Yield to maturity
—
Maturity date
Feb 1, 2026
XS308179796
Teva Pharmaceutical Finance Netherlands II BV 4.125% 01-JUN-2031
Yield to maturity
—
Maturity date
Jun 1, 2031
XS240660709
Teva Pharmaceutical Finance Netherlands II BV 3.75% 09-MAY-2027
Yield to maturity
—
Maturity date
May 9, 2027

See all TEVJF bonds 

Frequently Asked Questions


The current price of TEVJF is 14.32 USD — it has increased by 2.29% in the past 24 hours. Watch Teva Pharmaceutical Industries Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Teva Pharmaceutical Industries Ltd. stocks are traded under the ticker TEVJF.
We've gathered analysts' opinions on Teva Pharmaceutical Industries Ltd. future price: according to them, TEVJF price has a max estimate of 29.37 USD and a min estimate of 22.26 USD. Watch TEVJF chart and read a more detailed Teva Pharmaceutical Industries Ltd. stock forecast: see what analysts think of Teva Pharmaceutical Industries Ltd. and suggest that you do with its stocks.
TEVJF reached its all-time high on Jul 27, 2015 with the price of 69.24 USD, and its all-time low was 4.00 USD and was reached on Oct 7, 2019. View more price dynamics on TEVJF chart.
See other stocks reaching their highest and lowest prices.
TEVJF stock is 2.23% volatile and has beta coefficient of −0.23. Track Teva Pharmaceutical Industries Ltd. stock price on the chart and check out the list of the most volatile stocks — is Teva Pharmaceutical Industries Ltd. there?
Today Teva Pharmaceutical Industries Ltd. has the market capitalization of ‪21.57 B‬, it has decreased by −1.02% over the last week.
Yes, you can track Teva Pharmaceutical Industries Ltd. financials in yearly and quarterly reports right on TradingView.
Teva Pharmaceutical Industries Ltd. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
TEVJF earnings for the last quarter are 0.66 USD per share, whereas the estimation was 0.62 USD resulting in a 6.74% surprise. The estimated earnings for the next quarter are 0.68 USD per share. See more details about Teva Pharmaceutical Industries Ltd. earnings.
Teva Pharmaceutical Industries Ltd. revenue for the last quarter amounts to ‪4.17 B‬ USD, despite the estimated figure of ‪4.28 B‬ USD. In the next quarter, revenue is expected to reach ‪4.43 B‬ USD.
TEVJF net income for the last quarter is ‪298.36 M‬ USD, while the quarter before that showed ‪207.48 M‬ USD of net income which accounts for 43.80% change. Track more Teva Pharmaceutical Industries Ltd. financial stats to get the full picture.
No, TEVJF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has ‪36.17 K‬ employees. See our rating of the largest employees — is Teva Pharmaceutical Industries Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Teva Pharmaceutical Industries Ltd. EBITDA is ‪4.88 B‬ USD, and current EBITDA margin is 26.58%. See more stats in Teva Pharmaceutical Industries Ltd. financial statements.
Like other stocks, TEVJF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Teva Pharmaceutical Industries Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Teva Pharmaceutical Industries Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Teva Pharmaceutical Industries Ltd. stock shows the neutral signal. See more of Teva Pharmaceutical Industries Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.